Global Multiple Sclerosis Treatment Market- Global Industry Analysis And Forecast (2020-2027) – By Drug Type, Route Of Administration, Diagnosis, Distribution Channel, And Region.

Global Multiple Sclerosis Treatment Market anticipated reaching around US$ 25.27 Bn by 2027, growing at a CAGR of 6.7% and was worth US$ 23.52 Bn in 2019. To know about the Research Methodology :- Request Free Sample Report

Global Multiple Sclerosis Treatment Market Definition:

Multiple sclerosis (MS) is a chronic demyelinating autoimmune disease of the central nervous system (CNS) that disrupts the flow of signals within the brain and other parts of the body. The major cause of failure observed is heterogeneity in MS population and mental disturbances, psychological, and double vision are some major problems involved. Treatment usually focuses to provide speedy recovery, relapse the progression as there is no complete cure to (MS). The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Global Multiple Sclerosis Treatment Market Dynamics:

The report comprises of various segments as well an analysis of the trends and factors that are playing a substantial role in the market. These factors, involves the drivers, restraints, opportunities and challenges for the key companies and stake holders in the industry. The ultimate need of drugs for multiple sclerosis treatment, increased the number of R&D, increasing healthcare expenditure in different economies and occurrence of the MS disease are studied and analysed in the report with market size estimation and key players contribution in it. Growing awareness of MS is estimated to improve the drugs therapeutic and will increase the demand for treatment available for the disease. Moreover, the accessibility of new drugs and clinical studies on multiple sclerosis are major factors anticipated the market growth. However, stringent regulation for drug approval by the FDA and patent expiry contribute towards key restraint for the MS market. As per Atlas MS, around 2.3 Mn people suffer from MS, out of which many are not diagnosed due to lack of awareness and less no of healthcare infrastructure in certain parts. Also, the high cost in repeated trials for several therapeutic drugs repeated trials restrict the growth of this market.

Global Multiple Sclerosis Treatment Market Opportunities:

• Rising research and development investment to develop more effective drugs. • The progressions in the biomedical science for multiple sclerosis drug makers are about to create profitable opportunities in the upcoming forecast.

Global Multiple Sclerosis Treatment Market Key Developments in the Market:

• In 16, January 2019: Feinberg School of Medicine Northwestern University, researchers in a clinical trial found that while most of the patients on standard therapy were showing progression, the vast majority of patients did not show any progression who previously experienced the stem cell transplant. An experimental treatment is now showing progress, which was conducted for multiple sclerosis. • In March 2017, US FDA approach to approving Ocrelizumab, which targets the cells and considers as the main root for the Multiple Sclerosis development. • In August 2016 Pharmaceuticals Industries Teva took over Allergan PLC’s generic company called “Actavis Generics”.

Global Multiple Sclerosis Treatment Market: Market Segmentation:

The report covers competitive analysis of the Multiple Sclerosis Treatment market in each of the geographical segments thereby providing insight into a market share at the macro as well as micro levels. Immunomodulators dominate the market with the highest share of 7.2% in 2019 and are projected to grow rapidly during the forecast, mainly because of the rising research and development (R&D) activities and the increasing number of clinical studies that propel the growth rate. Furthermore, abundant treatment option and launch of the new product with rising in demand of popular drugs such as ocrevus and rebif drive the market growth. Moreover, approval by the FDA for mayzent is anticipated to fuel the growth. Based on Route of administration, the injection has the maximum share and high revenue of XX% in 2019 and is projected to grow at the highest CAGR of XX.X% by 2027. Injection contributes for largest growth because of higher efficacy of drugs with better drug delivery, better adsorption rate, raising awareness and market approvals of injectable products with high treatment costs for Multiple Sclerosis, Additionally, increasing per-capita income and increasing healthcare expenditure. Intramuscular (IM), Intravenous (IV), and subcutaneous (SC) are the three most regularly used injection routes. Also, drug by IV route is supposed to have 100% bioavailability.

Global Multiple Sclerosis Treatment market: Regional analysis

North America’s Multiple Sclerosis Treatment market was valued at US$ XX million in 2019 and is expected to reach a value of US$ XX million by 2027, with a CAGR of XX%. In North America, U.S. accounted to dominate the overall market to have the largest share of $10bn .U.S. spends around US$ 0.028 Bn every year for the multiple sclerosis treatment. Growing occurrence of Multiple sclerosis in the region with more number of hospitalization trials available in the US followed by Canada, technological advancements and development of Multiple Sclerosis treatments. According to the Lancet journal, about 2,221,188 cases of multiple sclerosis predominant around the world. The ASMR occurrence of this disorder was higher per 100,000 cases than 120 people in North America. The treatment market for multiple sclerosis is recorded to anticipate at CAGR 6%.In Asian pacific developing region like India and China have benefit for the drug creators over the developed countries because of the reasonable price of production.

Competitive Analysis: Global Multiple Sclerosis Treatment Market:

The competitive landscape section in the Multiple Sclerosis Treatment Market highly fragmented and the offers various strategies such as agreements, new product launches, partnerships expansions, acquisitions, joint ventures, and other crucial aspects to lessen the competitive in the market. Numerous pharmaceuticals corporations are experiencing clinical trials for multiple sclerosis treatment. Companies are to develop innovative therapies putting large expenditure in radiology for patients suffering from multiple sclerosis. Adamas Pharmaceuticals is also, experiencing phase 3 of a clinical trial on an amantadine agent called ADS-5102.

Scope of the Global Multiple Sclerosis Treatment Market: Inquire before buying

Global Multiple Sclerosis Treatment Market, By Drug Type

• Immunomodulatory  Ponesimod    Glatopa    Copaxone    Avonex    Fingolimod    Teriflunomide    Others • Immunosuppressant Cladribine    Others • Interferons  Betaseron    Others • Corticosteroids  Prednisone   Methylprednisolone   Others

Global Multiple Sclerosis Treatment Market, By Route of Administration

• Oral • Parenteral    Intramuscular    Subcutaneous    Intravenous

Global Multiple Sclerosis Treatment Market, By Diagnosis

• Magnetic Reasoning Imaging (MRI) Scan • Simple Electrical stimulation tests • Lumbar puncture • others

Global Multiple Sclerosis Treatment Market,By Distribution Channel

• Hospital Pharmacy • Retail Pharmacy • Online Stores

Global Multiple Sclerosis Treatment Market ,By Region

• North America • Europe • Asia Pacific • Middle East and Africa • Latin America

Global Multiple Sclerosis Treatment Market, key Players

• Bayer • Biogen • Merck KGaA • Teva • Sanofi • Novartis • Roche • Acorda Therapeutics, Inc. • EMD Serono (Merck KGaA) • AbbVie, Inc • Actelion • Celgene • AbbVie • Alkermes • TG Therapeutics • GeNeuro • Antisense Therapeutics • AB Science • MedDay • Coherus Bioscience • InnoBioscience • MediciNova • Santhera Pharmaceuticals • GSK • Ionis Pharmaceutical
Global Multiple Sclerosis Treatment Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Multiple Sclerosis Treatment Market Size, by Market Value (US$ Bn) & Volume (Unit) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Multiple Sclerosis Treatment Market Analysis and Forecast 6.1. Global Multiple Sclerosis Treatment Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Multiple Sclerosis Treatment Market Analysis and Forecast, By Drug Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Multiple Sclerosis Treatment Market Value Share Analysis, By Drug Type 7.4. Global Multiple Sclerosis Treatment Market Size (US$ Bn) Forecast, By Drug Type 7.5. Global Multiple Sclerosis Treatment Market Analysis, By Drug Type 7.6. Global Multiple Sclerosis Treatment Market Attractiveness Analysis, By Drug Type 8. Global Multiple Sclerosis Treatment Market Analysis and Forecast, By Route of Administration 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Multiple Sclerosis Treatment Market Value Share Analysis, By Route of Administration 8.4. Global Multiple Sclerosis Treatment Market Size (US$ Bn) Forecast, By Route of Administration 8.5. Global Multiple Sclerosis Treatment Market Analysis, By Route of Administration 8.6. Global Multiple Sclerosis Treatment Market Attractiveness Analysis, By Route of Administration 9. Global Multiple Sclerosis Treatment Market Analysis and Forecast, By Diagnosis 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Multiple Sclerosis Treatment Market Value Share Analysis, By Diagnosis 9.4. Global Multiple Sclerosis Treatment Market Size (US$ Bn) Forecast, By Diagnosis 9.5. Global Multiple Sclerosis Treatment Market Analysis, By Diagnosis 9.6. Global Multiple Sclerosis Treatment Market Attractiveness Analysis, By Diagnosis 10. Global Multiple Sclerosis Treatment Market Analysis and Forecast, By Distribution Channel 10.1. Introduction and Definition 10.2. Key Findings 10.3. Global Multiple Sclerosis Treatment Market Value Share Analysis, By Distribution Channel 10.4. Global Multiple Sclerosis Treatment Market Size (US$ Bn) Forecast, By Distribution Channel 10.5. Global Multiple Sclerosis Treatment Market Analysis, By Distribution Channel 10.6. Global Multiple Sclerosis Treatment Market Attractiveness Analysis, By Distribution Channel 11. Global Multiple Sclerosis Treatment Market Analysis, by Region 11.1. Global Multiple Sclerosis Treatment Market Value Share Analysis, by Region 11.2. Global Multiple Sclerosis Treatment Market Size (US$ Bn) Forecast, by Region 11.3. Global Multiple Sclerosis Treatment Market Attractiveness Analysis, by Region 12. North America Multiple Sclerosis Treatment Market Analysis 12.1. Key Findings 12.2. North America Multiple Sclerosis Treatment Market Overview 12.3. North America Multiple Sclerosis Treatment Market Value Share Analysis, By Drug Type 12.4. North America Multiple Sclerosis Treatment Market Forecast, By Drug Type 12.4.1. Immunomodulatory 12.4.1.1. Ponesimod 12.4.1.2. Glatopa 12.4.1.3. Copaxone 12.4.1.4. Avonex 12.4.1.5. Fingolimod 12.4.1.6. Teriflunomide 12.4.1.7. Others 12.4.2. Immunosuppressant 12.4.2.1. Cladribine 12.4.2.2. Others 12.4.3. Interferons 12.4.3.1. Betaseron 12.4.3.2. Others 12.4.4. Corticosteroids 12.4.4.1. Prednisone 12.4.4.2. Methylprednisolone 12.4.4.3. Others 12.5. North America Multiple Sclerosis Treatment Market Value Share Analysis, By Route of Administration 12.6. North America Multiple Sclerosis Treatment Market Forecast, By Route of Administration 12.6.1. Oral 12.6.2. Parenteral 12.6.2.1. Intramuscular 12.6.2.2. Subcutaneous 12.6.2.3. Intravenous 12.7. North America Multiple Sclerosis Treatment Market Value Share Analysis, By Diagnosis 12.8. North America Multiple Sclerosis Treatment Market Forecast, By Diagnosis 12.8.1. Magnetic Reasoning Imaging (MRI) Scan 12.8.2. Simple Electrical stimulation tests 12.8.3. Lumbar puncture 12.8.4. others 12.9. North America Multiple Sclerosis Treatment Market Value Share Analysis, By Distribution Channel 12.10. North America Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 12.10.1. Hospital Pharmacy 12.10.2. Retail Pharmacy 12.10.3. Online Stores 12.11. North America Multiple Sclerosis Treatment Market Value Share Analysis, by Country 12.12. North America Multiple Sclerosis Treatment Market Forecast, by Country 12.12.1. U.S. 12.12.2. Canada 12.13. North America Multiple Sclerosis Treatment Market Analysis, by Country 12.14. U.S. Multiple Sclerosis Treatment Market Forecast, By Drug Type 12.14.1. Immunomodulatory 12.14.1.1. Ponesimod 12.14.1.2. Glatopa 12.14.1.3. Copaxone 12.14.1.4. Avonex 12.14.1.5. Fingolimod 12.14.1.6. Teriflunomide 12.14.1.7. Others 12.14.2. Immunosuppressant 12.14.2.1. Cladribine 12.14.2.2. Others 12.14.3. Interferons 12.14.3.1. Betaseron 12.14.3.2. Others 12.14.4. Corticosteroids 12.14.4.1. Prednisone 12.14.4.2. Methylprednisolone 12.14.4.3. Others 12.15. U.S. Multiple Sclerosis Treatment Market Forecast, By Route of Administration 12.15.1. Oral 12.15.2. Parenteral 12.15.2.1. Intramuscular 12.15.2.2. Subcutaneous 12.15.2.3. Intravenous 12.16. U.S. Multiple Sclerosis Treatment Market Forecast, By Diagnosis 12.16.1. Magnetic Reasoning Imaging (MRI) Scan 12.16.2. Simple Electrical stimulation tests 12.16.3. Lumbar puncture 12.16.4. others 12.17. U.S. Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 12.17.1. Hospital Pharmacy 12.17.2. Retail Pharmacy 12.17.3. Online Stores 12.18. Canada Multiple Sclerosis Treatment Market Forecast, By Drug Type 12.18.1. Immunomodulatory 12.18.1.1. Ponesimod 12.18.1.2. Glatopa 12.18.1.3. Copaxone 12.18.1.4. Avonex 12.18.1.5. Fingolimod 12.18.1.6. Teriflunomide 12.18.1.7. Others 12.18.2. Immunosuppressant 12.18.2.1. Cladribine 12.18.2.2. Others 12.18.3. Interferons 12.18.3.1. Betaseron 12.18.3.2. Others 12.18.4. Corticosteroids 12.18.4.1. Prednisone 12.18.4.2. Methylprednisolone 12.18.4.3. Others 12.19. Canada Multiple Sclerosis Treatment Market Forecast, By Route of Administration 12.19.1. Oral 12.19.2. Parenteral 12.19.2.1. Intramuscular 12.19.2.2. Subcutaneous 12.19.2.3. Intravenous 12.20. Canada Multiple Sclerosis Treatment Market Forecast, By Diagnosis 12.20.1. Magnetic Reasoning Imaging (MRI) Scan 12.20.2. Simple Electrical stimulation tests 12.20.3. Lumbar puncture 12.20.4. others 12.21. Canada Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 12.21.1. Hospital Pharmacy 12.21.2. Retail Pharmacy 12.21.3. Online Stores 12.22. North America Multiple Sclerosis Treatment Market Attractiveness Analysis 12.22.1. By Drug Type 12.22.2. By Route of Administration 12.22.3. By Diagnosis 12.22.4. By Distribution Channel 12.23. PEST Analysis 12.24. Key Trends 12.25. Key Developments 13. Europe Multiple Sclerosis Treatment Market Analysis 13.1. Key Findings 13.2. Europe Multiple Sclerosis Treatment Market Overview 13.3. Europe Multiple Sclerosis Treatment Market Value Share Analysis, By Drug Type 13.4. Europe Multiple Sclerosis Treatment Market Forecast, By Drug Type 13.4.1. Immunomodulatory 13.4.1.1. Ponesimod 13.4.1.2. Glatopa 13.4.1.3. Copaxone 13.4.1.4. Avonex 13.4.1.5. Fingolimod 13.4.1.6. Teriflunomide 13.4.1.7. Others 13.4.2. Immunosuppressant 13.4.2.1. Cladribine 13.4.2.2. Others 13.4.3. Interferons 13.4.3.1. Betaseron 13.4.3.2. Others 13.4.4. Corticosteroids 13.4.4.1. Prednisone 13.4.4.2. Methylprednisolone 13.4.4.3. Others 13.5. Europe Multiple Sclerosis Treatment Market Value Share Analysis, By Route of Administration 13.6. Europe Multiple Sclerosis Treatment Market Forecast, By Route of Administration 13.6.1. Oral 13.6.2. Parenteral 13.6.2.1. Intramuscular 13.6.2.2. Subcutaneous 13.6.2.3. Intravenous 13.7. Europe Multiple Sclerosis Treatment Market Value Share Analysis, By Diagnosis 13.8. Europe Multiple Sclerosis Treatment Market Forecast, By Diagnosis 13.8.1. Magnetic Reasoning Imaging (MRI) Scan 13.8.2. Simple Electrical stimulation tests 13.8.3. Lumbar puncture 13.8.4. others 13.9. Europe Multiple Sclerosis Treatment Market Value Share Analysis, By Distribution Channel 13.10. Europe Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 13.10.1. Hospital Pharmacy 13.10.2. Retail Pharmacy 13.10.3. Online Stores 13.11. Europe Multiple Sclerosis Treatment Market Value Share Analysis, by Country 13.12. Europe Multiple Sclerosis Treatment Market Forecast, by Country 13.12.1. Germany 13.12.2. U.K. 13.12.3. France 13.12.4. Italy 13.12.5. Spain 13.12.6. Rest of Europe 13.13. Europe Multiple Sclerosis Treatment Market Analysis, by Country 13.14. Germany Multiple Sclerosis Treatment Market Forecast, By Drug Type 13.14.1. Immunomodulatory 13.14.1.1. Ponesimod 13.14.1.2. Glatopa 13.14.1.3. Copaxone 13.14.1.4. Avonex 13.14.1.5. Fingolimod 13.14.1.6. Teriflunomide 13.14.1.7. Others 13.14.2. Immunosuppressant 13.14.2.1. Cladribine 13.14.2.2. Others 13.14.3. Interferons 13.14.3.1. Betaseron 13.14.3.2. Others 13.14.4. Corticosteroids 13.14.4.1. Prednisone 13.14.4.2. Methylprednisolone 13.14.4.3. Others 13.15. Germany Multiple Sclerosis Treatment Market Forecast, By Route of Administration 13.15.1. Oral 13.15.2. Parenteral 13.15.2.1. Intramuscular 13.15.2.2. Subcutaneous 13.15.2.3. Intravenous 13.16. Germany Multiple Sclerosis Treatment Market Forecast, By Diagnosis 13.16.1. Magnetic Reasoning Imaging (MRI) Scan 13.16.2. Simple Electrical stimulation tests 13.16.3. Lumbar puncture 13.16.4. others 13.17. Germany Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 13.17.1. Hospital Pharmacy 13.17.2. Retail Pharmacy 13.17.3. Online Stores 13.18. U.K. Multiple Sclerosis Treatment Market Forecast, By Drug Type 13.18.1. Immunomodulatory 13.18.1.1. Ponesimod 13.18.1.2. Glatopa 13.18.1.3. Copaxone 13.18.1.4. Avonex 13.18.1.5. Fingolimod 13.18.1.6. Teriflunomide 13.18.1.7. Others 13.18.2. Immunosuppressant 13.18.2.1. Cladribine 13.18.2.2. Others 13.18.3. Interferons 13.18.3.1. Betaseron 13.18.3.2. Others 13.18.4. Corticosteroids 13.18.4.1. Prednisone 13.18.4.2. Methylprednisolone 13.18.4.3. Others 13.19. U.K. Multiple Sclerosis Treatment Market Forecast, By Route of Administration 13.19.1. Oral 13.19.2. Parenteral 13.19.2.1. Intramuscular 13.19.2.2. Subcutaneous 13.19.2.3. Intravenous 13.20. U.K. Multiple Sclerosis Treatment Market Forecast, By Diagnosis 13.20.1. Magnetic Reasoning Imaging (MRI) Scan 13.20.2. Simple Electrical stimulation tests 13.20.3. Lumbar puncture 13.20.4. others 13.21. U.K. Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 13.21.1. Hospital Pharmacy 13.21.2. Retail Pharmacy 13.21.3. Online Stores 13.22. France Multiple Sclerosis Treatment Market Forecast, By Drug Type 13.22.1. Immunomodulatory 13.22.1.1. Ponesimod 13.22.1.2. Glatopa 13.22.1.3. Copaxone 13.22.1.4. Avonex 13.22.1.5. Fingolimod 13.22.1.6. Teriflunomide 13.22.1.7. Others 13.22.2. Immunosuppressant 13.22.2.1. Cladribine 13.22.2.2. Others 13.22.3. Interferons 13.22.3.1. Betaseron 13.22.3.2. Others 13.22.4. Corticosteroids 13.22.4.1. Prednisone 13.22.4.2. Methylprednisolone 13.22.4.3. Others 13.23. France Multiple Sclerosis Treatment Market Forecast, By Route of Administration 13.23.1. Oral 13.23.2. Parenteral 13.23.2.1. Intramuscular 13.23.2.2. Subcutaneous 13.23.2.3. Intravenous 13.24. France Multiple Sclerosis Treatment Market Forecast, By Diagnosis 13.24.1. Magnetic Reasoning Imaging (MRI) Scan 13.24.2. Simple Electrical stimulation tests 13.24.3. Lumbar puncture 13.24.4. others 13.25. France Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 13.25.1. Hospital Pharmacy 13.25.2. Retail Pharmacy 13.25.3. Online Stores 13.26. Italy Multiple Sclerosis Treatment Market Forecast, By Drug Type 13.26.1. Immunomodulatory 13.26.1.1. Ponesimod 13.26.1.2. Glatopa 13.26.1.3. Copaxone 13.26.1.4. Avonex 13.26.1.5. Fingolimod 13.26.1.6. Teriflunomide 13.26.1.7. Others 13.26.2. Immunosuppressant 13.26.2.1. Cladribine 13.26.2.2. Others 13.26.3. Interferons 13.26.3.1. Betaseron 13.26.3.2. Others 13.26.4. Corticosteroids 13.26.4.1. Prednisone 13.26.4.2. Methylprednisolone 13.26.4.3. Others 13.27. Italy Multiple Sclerosis Treatment Market Forecast, By Route of Administration 13.27.1. Oral 13.27.2. Parenteral 13.27.2.1. Intramuscular 13.27.2.2. Subcutaneous 13.27.2.3. Intravenous 13.28. Italy Multiple Sclerosis Treatment Market Forecast, By Diagnosis 13.28.1. Magnetic Reasoning Imaging (MRI) Scan 13.28.2. Simple Electrical stimulation tests 13.28.3. Lumbar puncture 13.28.4. others 13.29. Italy Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 13.29.1. Hospital Pharmacy 13.29.2. Retail Pharmacy 13.29.3. Online Stores 13.30. Spain Multiple Sclerosis Treatment Market Forecast, By Drug Type 13.30.1. Immunomodulatory 13.30.1.1. Ponesimod 13.30.1.2. Glatopa 13.30.1.3. Copaxone 13.30.1.4. Avonex 13.30.1.5. Fingolimod 13.30.1.6. Teriflunomide 13.30.1.7. Others 13.30.2. Immunosuppressant 13.30.2.1. Cladribine 13.30.2.2. Others 13.30.3. Interferons 13.30.3.1. Betaseron 13.30.3.2. Others 13.30.4. Corticosteroids 13.30.4.1. Prednisone 13.30.4.2. Methylprednisolone 13.30.4.3. Others 13.31. Spain Multiple Sclerosis Treatment Market Forecast, By Route of Administration 13.31.1. Oral 13.31.2. Parenteral 13.31.2.1. Intramuscular 13.31.2.2. Subcutaneous 13.31.2.3. Intravenous 13.32. Spain Multiple Sclerosis Treatment Market Forecast, By Diagnosis 13.32.1. Magnetic Reasoning Imaging (MRI) Scan 13.32.2. Simple Electrical stimulation tests 13.32.3. Lumbar puncture 13.32.4. others 13.33. Spain Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 13.33.1. Hospital Pharmacy 13.33.2. Retail Pharmacy 13.33.3. Online Stores 13.34. Rest of Europe Multiple Sclerosis Treatment Market Forecast, By Drug Type 13.34.1. Immunomodulatory 13.34.1.1. Ponesimod 13.34.1.2. Glatopa 13.34.1.3. Copaxone 13.34.1.4. Avonex 13.34.1.5. Fingolimod 13.34.1.6. Teriflunomide 13.34.1.7. Others 13.34.2. Immunosuppressant 13.34.2.1. Cladribine 13.34.2.2. Others 13.34.3. Interferons 13.34.3.1. Betaseron 13.34.3.2. Others 13.34.4. Corticosteroids 13.34.4.1. Prednisone 13.34.4.2. Methylprednisolone 13.34.4.3. Others 13.35. Rest of Europe Multiple Sclerosis Treatment Market Forecast, By Route of Administration 13.35.1. Oral 13.35.2. Parenteral 13.35.2.1. Intramuscular 13.35.2.2. Subcutaneous 13.35.2.3. Intravenous 13.36. Rest of Europe Multiple Sclerosis Treatment Market Forecast, By Diagnosis 13.36.1. Magnetic Reasoning Imaging (MRI) Scan 13.36.2. Simple Electrical stimulation tests 13.36.3. Lumbar puncture 13.36.4. others 13.37. Rest Of Europe Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 13.37.1. Hospital Pharmacy 13.37.2. Retail Pharmacy 13.37.3. Online Stores 13.38. Europe Multiple Sclerosis Treatment Market Attractiveness Analysis 13.38.1. By Drug Type 13.38.2. By Route of Administration 13.38.3. By Diagnosis 13.38.4. By Distribution Channel 13.39. PEST Analysis 13.40. Key Trends 13.41. Key Developments 14. Asia Pacific Multiple Sclerosis Treatment Market Analysis 14.1. Key Findings 14.2. Asia Pacific Multiple Sclerosis Treatment Market Overview 14.3. Asia Pacific Multiple Sclerosis Treatment Market Value Share Analysis, By Drug Type 14.4. Asia Pacific Multiple Sclerosis Treatment Market Forecast, By Drug Type 14.4.1. Immunomodulatory 14.4.1.1. Ponesimod 14.4.1.2. Glatopa 14.4.1.3. Copaxone 14.4.1.4. Avonex 14.4.1.5. Fingolimod 14.4.1.6. Teriflunomide 14.4.1.7. Others 14.4.2. Immunosuppressant 14.4.2.1. Cladribine 14.4.2.2. Others 14.4.3. Interferons 14.4.3.1. Betaseron 14.4.3.2. Others 14.4.4. Corticosteroids 14.4.4.1. Prednisone 14.4.4.2. Methylprednisolone 14.4.4.3. Others 14.5. Asia Pacific Multiple Sclerosis Treatment Market Value Share Analysis, By Route of Administration 14.6. Asia Pacific Multiple Sclerosis Treatment Market Forecast, By Route of Administration 14.6.1. Oral 14.6.2. Parenteral 14.6.2.1. Intramuscular 14.6.2.2. Subcutaneous 14.6.2.3. Intravenous 14.7. Asia Pacific Multiple Sclerosis Treatment Market Value Share Analysis, By Diagnosis 14.8. Asia Pacific Multiple Sclerosis Treatment Market Forecast, By Diagnosis 14.8.1. Magnetic Reasoning Imaging (MRI) Scan 14.8.2. Simple Electrical stimulation tests 14.8.3. Lumbar puncture 14.8.4. others 14.9. Asia Pacific Multiple Sclerosis Treatment Market Value Share Analysis, By Distribution Channel 14.10. Asia Pacific Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 14.10.1. Hospital Pharmacy 14.10.2. Retail Pharmacy 14.10.3. Online Stores 14.11. Asia Pacific Multiple Sclerosis Treatment Market Value Share Analysis, by Country 14.12. Asia Pacific Multiple Sclerosis Treatment Market Forecast, by Country 14.12.1. China 14.12.2. India 14.12.3. Japan 14.12.4. ASEAN 14.12.5. Rest of Asia Pacific 14.13. Asia Pacific Multiple Sclerosis Treatment Market Analysis, by Country 14.14. China Multiple Sclerosis Treatment Market Forecast, By Drug Type 14.14.1. Immunomodulatory 14.14.1.1. Ponesimod 14.14.1.2. Glatopa 14.14.1.3. Copaxone 14.14.1.4. Avonex 14.14.1.5. Fingolimod 14.14.1.6. Teriflunomide 14.14.1.7. Others 14.14.2. Immunosuppressant 14.14.2.1. Cladribine 14.14.2.2. Others 14.14.3. Interferons 14.14.3.1. Betaseron 14.14.3.2. Others 14.14.4. Corticosteroids 14.14.4.1. Prednisone 14.14.4.2. Methylprednisolone 14.14.4.3. Others 14.15. China Multiple Sclerosis Treatment Market Forecast, By Route of Administration 14.15.1. Oral 14.15.2. Parenteral 14.15.2.1. Intramuscular 14.15.2.2. Subcutaneous 14.15.2.3. Intravenous 14.16. China Multiple Sclerosis Treatment Market Forecast, By Diagnosis 14.16.1. Magnetic Reasoning Imaging (MRI) Scan 14.16.2. Simple Electrical stimulation tests 14.16.3. Lumbar puncture 14.16.4. others 14.17. China Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 14.17.1. Hospital Pharmacy 14.17.2. Retail Pharmacy 14.17.3. Online Stores 14.18. India Multiple Sclerosis Treatment Market Forecast, By Drug Type 14.18.1. Immunomodulatory 14.18.1.1. Ponesimod 14.18.1.2. Glatopa 14.18.1.3. Copaxone 14.18.1.4. Avonex 14.18.1.5. Fingolimod 14.18.1.6. Teriflunomide 14.18.1.7. Others 14.18.2. Immunosuppressant 14.18.2.1. Cladribine 14.18.2.2. Others 14.18.3. Interferons 14.18.3.1. Betaseron 14.18.3.2. Others 14.18.4. Corticosteroids 14.18.4.1. Prednisone 14.18.4.2. Methylprednisolone 14.18.4.3. Others 14.19. India Multiple Sclerosis Treatment Market Forecast, By Route of Administration 14.19.1. Oral 14.19.2. Parenteral 14.19.2.1. Intramuscular 14.19.2.2. Subcutaneous 14.19.2.3. Intravenous 14.20. India Multiple Sclerosis Treatment Market Forecast, By Diagnosis 14.20.1. Magnetic Reasoning Imaging (MRI) Scan 14.20.2. Simple Electrical stimulation tests 14.20.3. Lumbar puncture 14.20.4. others 14.21. India Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 14.21.1. Hospital Pharmacy 14.21.2. Retail Pharmacy 14.21.3. Online Stores 14.22. Japan Multiple Sclerosis Treatment Market Forecast, By Drug Type 14.22.1. Immunomodulatory 14.22.1.1. Ponesimod 14.22.1.2. Glatopa 14.22.1.3. Copaxone 14.22.1.4. Avonex 14.22.1.5. Fingolimod 14.22.1.6. Teriflunomide 14.22.1.7. Others 14.22.2. Immunosuppressant 14.22.2.1. Cladribine 14.22.2.2. Others 14.22.3. Interferons 14.22.3.1. Betaseron 14.22.3.2. Others 14.22.4. Corticosteroids 14.22.4.1. Prednisone 14.22.4.2. Methylprednisolone 14.22.4.3. Others 14.23. Japan Multiple Sclerosis Treatment Market Forecast, By Route of Administration 14.23.1. Oral 14.23.2. Parenteral 14.23.2.1. Intramuscular 14.23.2.2. Subcutaneous 14.23.2.3. Intravenous 14.24. Japan Multiple Sclerosis Treatment Market Forecast, By Diagnosis 14.24.1. Magnetic Reasoning Imaging (MRI) Scan 14.24.2. Simple Electrical stimulation tests 14.24.3. Lumbar puncture 14.24.4. others 14.25. Japan Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 14.25.1. Hospital Pharmacy 14.25.2. Retail Pharmacy 14.25.3. Online Stores 14.26. ASEAN Multiple Sclerosis Treatment Market Forecast, By Drug Type 14.26.1. Immunomodulatory 14.26.1.1. Ponesimod 14.26.1.2. Glatopa 14.26.1.3. Copaxone 14.26.1.4. Avonex 14.26.1.5. Fingolimod 14.26.1.6. Teriflunomide 14.26.1.7. Others 14.26.2. Immunosuppressant 14.26.2.1. Cladribine 14.26.2.2. Others 14.26.3. Interferons 14.26.3.1. Betaseron 14.26.3.2. Others 14.26.4. Corticosteroids 14.26.4.1. Prednisone 14.26.4.2. Methylprednisolone 14.26.4.3. Others 14.27. ASEAN Multiple Sclerosis Treatment Market Forecast, By Route of Administration 14.27.1. Oral 14.27.2. Parenteral 14.27.2.1. Intramuscular 14.27.2.2. Subcutaneous 14.27.2.3. Intravenous 14.28. ASEAN Multiple Sclerosis Treatment Market Forecast, By Diagnosis 14.28.1. Magnetic Reasoning Imaging (MRI) Scan 14.28.2. Simple Electrical stimulation tests 14.28.3. Lumbar puncture 14.28.4. others 14.29. ASEAN Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 14.29.1. Hospital Pharmacy 14.29.2. Retail Pharmacy 14.29.3. Online Stores 14.30. Rest of Asia Pacific Multiple Sclerosis Treatment Market Forecast, By Drug Type 14.30.1. Immunomodulatory 14.30.1.1. Ponesimod 14.30.1.2. Glatopa 14.30.1.3. Copaxone 14.30.1.4. Avonex 14.30.1.5. Fingolimod 14.30.1.6. Teriflunomide 14.30.1.7. Others 14.30.2. Immunosuppressant 14.30.2.1. Cladribine 14.30.2.2. Others 14.30.3. Interferons 14.30.3.1. Betaseron 14.30.3.2. Others 14.30.4. Corticosteroids 14.30.4.1. Prednisone 14.30.4.2. Methylprednisolone 14.30.4.3. Others 14.31. Rest of Asia Pacific Multiple Sclerosis Treatment Market Forecast, By Route of Administration 14.31.1. Oral 14.31.2. Parenteral 14.31.2.1. Intramuscular 14.31.2.2. Subcutaneous 14.31.2.3. Intravenous 14.32. Rest of Asia Pacific Multiple Sclerosis Treatment Market Forecast, By Diagnosis 14.32.1. Magnetic Reasoning Imaging (MRI) Scan 14.32.2. Simple Electrical stimulation tests 14.32.3. Lumbar puncture 14.32.4. others 14.33. Rest of Asia Pacific Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 14.33.1. Hospital Pharmacy 14.33.2. Retail Pharmacy 14.33.3. Online Stores 14.34. Asia Pacific Multiple Sclerosis Treatment Market Attractiveness Analysis 14.34.1. By Drug Type 14.34.2. By Route of Administration 14.34.3. By Diagnosis 14.34.4. By Distribution Channel 14.35. PEST Analysis 14.36. Key Trends 14.37. Key Developments 15. Middle East & Africa Multiple Sclerosis Treatment Market Analysis 15.1. Key Findings 15.2. Middle East & Africa Multiple Sclerosis Treatment Market Overview 15.3. Middle East & Africa Multiple Sclerosis Treatment Market Value Share Analysis, By Drug Type 15.4. Middle East & Africa Multiple Sclerosis Treatment Market Forecast, By Drug Type 15.4.1. Immunomodulatory 15.4.1.1. Ponesimod 15.4.1.2. Glatopa 15.4.1.3. Copaxone 15.4.1.4. Avonex 15.4.1.5. Fingolimod 15.4.1.6. Teriflunomide 15.4.1.7. Others 15.4.2. Immunosuppressant 15.4.2.1. Cladribine 15.4.2.2. Others 15.4.3. Interferons 15.4.3.1. Betaseron 15.4.3.2. Others 15.4.4. Corticosteroids 15.4.4.1. Prednisone 15.4.4.2. Methylprednisolone 15.4.4.3. Others 15.5. Middle East & Africa Multiple Sclerosis Treatment Market Value Share Analysis, By Route of Administration 15.6. Middle East & Africa Multiple Sclerosis Treatment Market Forecast, By Route of Administration 15.6.1. Oral 15.6.2. Parenteral 15.6.2.1. Intramuscular 15.6.2.2. Subcutaneous 15.6.2.3. Intravenous 15.7. Middle East & Africa Multiple Sclerosis Treatment Market Value Share Analysis, By Diagnosis 15.8. Middle East & Africa Multiple Sclerosis Treatment Market Forecast, By Diagnosis 15.8.1. Magnetic Reasoning Imaging (MRI) Scan 15.8.2. Simple Electrical stimulation tests 15.8.3. Lumbar puncture 15.8.4. others 15.9. Middle East & Africa Multiple Sclerosis Treatment Market Value Share Analysis, By Distribution Channel 15.10. Middle East & Africa Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 15.10.1. Hospital Pharmacy 15.10.2. Retail Pharmacy 15.10.3. Online Stores 15.11. Middle East & Africa Multiple Sclerosis Treatment Market Value Share Analysis, by Country 15.12. Middle East & Africa Multiple Sclerosis Treatment Market Forecast, by Country 15.12.1. GCC 15.12.2. South Africa 15.12.3. Rest of Middle East & Africa 15.13. Middle East & Africa Multiple Sclerosis Treatment Market Analysis, by Country 15.14. GCC Multiple Sclerosis Treatment Market Forecast, By Drug Type 15.14.1. Immunomodulatory 15.14.1.1. Ponesimod 15.14.1.2. Glatopa 15.14.1.3. Copaxone 15.14.1.4. Avonex 15.14.1.5. Fingolimod 15.14.1.6. Teriflunomide 15.14.1.7. Others 15.14.2. Immunosuppressant 15.14.2.1. Cladribine 15.14.2.2. Others 15.14.3. Interferons 15.14.3.1. Betaseron 15.14.3.2. Others 15.14.4. Corticosteroids 15.14.4.1. Prednisone 15.14.4.2. Methylprednisolone 15.14.4.3. Others 15.15. GCC Multiple Sclerosis Treatment Market Forecast, By Route of Administration 15.15.1. Oral 15.15.2. Parenteral 15.15.2.1. Intramuscular 15.15.2.2. Subcutaneous 15.15.2.3. Intravenous 15.16. GCC Multiple Sclerosis Treatment Market Forecast, By Diagnosis 15.16.1. Magnetic Reasoning Imaging (MRI) Scan 15.16.2. Simple Electrical stimulation tests 15.16.3. Lumbar puncture 15.16.4. others 15.17. GCC Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 15.17.1. Hospital Pharmacy 15.17.2. Retail Pharmacy 15.17.3. Online Stores 15.18. South Africa Multiple Sclerosis Treatment Market Forecast, By Drug Type 15.18.1. Immunomodulatory 15.18.1.1. Ponesimod 15.18.1.2. Glatopa 15.18.1.3. Copaxone 15.18.1.4. Avonex 15.18.1.5. Fingolimod 15.18.1.6. Teriflunomide 15.18.1.7. Others 15.18.2. Immunosuppressant 15.18.2.1. Cladribine 15.18.2.2. Others 15.18.3. Interferons 15.18.3.1. Betaseron 15.18.3.2. Others 15.18.4. Corticosteroids 15.18.4.1. Prednisone 15.18.4.2. Methylprednisolone 15.18.4.3. Others 15.19. South Africa Multiple Sclerosis Treatment Market Forecast, By Route of Administration 15.19.1. Oral 15.19.2. Parenteral 15.19.2.1. Intramuscular 15.19.2.2. Subcutaneous 15.19.2.3. Intravenous 15.20. South Africa Multiple Sclerosis Treatment Market Forecast, By Diagnosis 15.20.1. Magnetic Reasoning Imaging (MRI) Scan 15.20.2. Simple Electrical stimulation tests 15.20.3. Lumbar puncture 15.20.4. others 15.21. South Africa Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 15.21.1. Hospital Pharmacy 15.21.2. Retail Pharmacy 15.21.3. Online Stores 15.22. Rest of Middle East & Africa Multiple Sclerosis Treatment Market Forecast, By Drug Type 15.22.1. Immunomodulatory 15.22.1.1. Ponesimod 15.22.1.2. Glatopa 15.22.1.3. Copaxone 15.22.1.4. Avonex 15.22.1.5. Fingolimod 15.22.1.6. Teriflunomide 15.22.1.7. Others 15.22.2. Immunosuppressant 15.22.2.1. Cladribine 15.22.2.2. Others 15.22.3. Interferons 15.22.3.1. Betaseron 15.22.3.2. Others 15.22.4. Corticosteroids 15.22.4.1. Prednisone 15.22.4.2. Methylprednisolone 15.22.4.3. Others 15.23. Rest of Middle East & Africa Multiple Sclerosis Treatment Market Forecast, By Route of Administration 15.23.1. Oral 15.23.2. Parenteral 15.23.2.1. Intramuscular 15.23.2.2. Subcutaneous 15.23.2.3. Intravenous 15.24. Rest of Middle East & Africa Multiple Sclerosis Treatment Market Forecast, By Diagnosis 15.24.1. Magnetic Reasoning Imaging (MRI) Scan 15.24.2. Simple Electrical stimulation tests 15.24.3. Lumbar puncture 15.24.4. others 15.25. Rest of Middle East & Africa Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 15.25.1. Hospital Pharmacy 15.25.2. Retail Pharmacy 15.25.3. Online Stores 15.26. Middle East & Africa Multiple Sclerosis Treatment Market Attractiveness Analysis 15.26.1. By Drug Type 15.26.2. By Route of Administration 15.26.3. By Diagnosis 15.26.4. By Distribution Channel 15.27. PEST Analysis 15.28. Key Trends 15.29. Key Developments 16. South America Multiple Sclerosis Treatment Market Analysis 16.1. Key Findings 16.2. South America Multiple Sclerosis Treatment Market Overview 16.3. South America Multiple Sclerosis Treatment Market Value Share Analysis, By Drug Type 16.4. South America Multiple Sclerosis Treatment Market Forecast, By Drug Type 16.4.1. Immunomodulatory 16.4.1.1. Ponesimod 16.4.1.2. Glatopa 16.4.1.3. Copaxone 16.4.1.4. Avonex 16.4.1.5. Fingolimod 16.4.1.6. Teriflunomide 16.4.1.7. Others 16.4.2. Immunosuppressant 16.4.2.1. Cladribine 16.4.2.2. Others 16.4.3. Interferons 16.4.3.1. Betaseron 16.4.3.2. Others 16.4.4. Corticosteroids 16.4.4.1. Prednisone 16.4.4.2. Methylprednisolone 16.4.4.3. Others 16.5. South America Multiple Sclerosis Treatment Market Value Share Analysis, By Route of Administration 16.6. South America Multiple Sclerosis Treatment Market Forecast, By Route of Administration 16.6.1. Oral 16.6.2. Parenteral 16.6.2.1. Intramuscular 16.6.2.2. Subcutaneous 16.6.2.3. Intravenous 16.7. South America Multiple Sclerosis Treatment Market Value Share Analysis, By Diagnosis 16.8. South America Multiple Sclerosis Treatment Market Forecast, By Diagnosis 16.8.1. Magnetic Reasoning Imaging (MRI) Scan 16.8.2. Simple Electrical stimulation tests 16.8.3. Lumbar puncture 16.8.4. others 16.9. South America Multiple Sclerosis Treatment Market Value Share Analysis, By Distribution Channel 16.10. South America Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 16.10.1. Hospital Pharmacy 16.10.2. Retail Pharmacy 16.10.3. Online Stores 16.11. South America Multiple Sclerosis Treatment Market Value Share Analysis, by Country 16.12. South America Multiple Sclerosis Treatment Market Forecast, by Country 16.12.1. Brazil 16.12.2. Mexico 16.12.3. Rest of South America 16.13. South America Multiple Sclerosis Treatment Market Analysis, by Country 16.14. Brazil Multiple Sclerosis Treatment Market Forecast, By Drug Type 16.14.1. Immunomodulatory 16.14.1.1. Ponesimod 16.14.1.2. Glatopa 16.14.1.3. Copaxone 16.14.1.4. Avonex 16.14.1.5. Fingolimod 16.14.1.6. Teriflunomide 16.14.1.7. Others 16.14.2. Immunosuppressant 16.14.2.1. Cladribine 16.14.2.2. Others 16.14.3. Interferons 16.14.3.1. Betaseron 16.14.3.2. Others 16.14.4. Corticosteroids 16.14.4.1. Prednisone 16.14.4.2. Methylprednisolone 16.14.4.3. Others 16.15. Brazil Multiple Sclerosis Treatment Market Forecast, By Route of Administration 16.15.1. Oral 16.15.2. Parenteral 16.15.2.1. Intramuscular 16.15.2.2. Subcutaneous 16.15.2.3. Intravenous 16.16. Brazil Multiple Sclerosis Treatment Market Forecast, By Diagnosis 16.16.1. Magnetic Reasoning Imaging (MRI) Scan 16.16.2. Simple Electrical stimulation tests 16.16.3. Lumbar puncture 16.16.4. others 16.17. Brazil Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 16.17.1. Hospital Pharmacy 16.17.2. Retail Pharmacy 16.17.3. Online Stores 16.18. Mexico Multiple Sclerosis Treatment Market Forecast, By Drug Type 16.18.1. Immunomodulatory 16.18.1.1. Ponesimod 16.18.1.2. Glatopa 16.18.1.3. Copaxone 16.18.1.4. Avonex 16.18.1.5. Fingolimod 16.18.1.6. Teriflunomide 16.18.1.7. Others 16.18.2. Immunosuppressant 16.18.2.1. Cladribine 16.18.2.2. Others 16.18.3. Interferons 16.18.3.1. Betaseron 16.18.3.2. Others 16.18.4. Corticosteroids 16.18.4.1. Prednisone 16.18.4.2. Methylprednisolone 16.18.4.3. Others 16.19. Mexico Multiple Sclerosis Treatment Market Forecast, By Route of Administration 16.19.1. Oral 16.19.2. Parenteral 16.19.2.1. Intramuscular 16.19.2.2. Subcutaneous 16.19.2.3. Intravenous 16.20. Mexico Multiple Sclerosis Treatment Market Forecast, By Diagnosis 16.20.1. Magnetic Reasoning Imaging (MRI) Scan 16.20.2. Simple Electrical stimulation tests 16.20.3. Lumbar puncture 16.20.4. others 16.21. Mexico Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 16.21.1. Hospital Pharmacy 16.21.2. Retail Pharmacy 16.21.3. Online Stores 16.22. Rest of South America Multiple Sclerosis Treatment Market Forecast, By Drug Type 16.22.1. Immunomodulatory 16.22.1.1. Ponesimod 16.22.1.2. Glatopa 16.22.1.3. Copaxone 16.22.1.4. Avonex 16.22.1.5. Fingolimod 16.22.1.6. Teriflunomide 16.22.1.7. Others 16.22.2. Immunosuppressant 16.22.2.1. Cladribine 16.22.2.2. Others 16.22.3. Interferons 16.22.3.1. Betaseron 16.22.3.2. Others 16.22.4. Corticosteroids 16.22.4.1. Prednisone 16.22.4.2. Methylprednisolone 16.22.4.3. Others 16.23. Rest of South America Multiple Sclerosis Treatment Market Forecast, By Route of Administration 16.23.1. Oral 16.23.2. Parenteral 16.23.2.1. Intramuscular 16.23.2.2. Subcutaneous 16.23.2.3. Intravenous 16.24. Rest of South America Multiple Sclerosis Treatment Market Forecast, By Diagnosis 16.24.1. Magnetic Reasoning Imaging (MRI) Scan 16.24.2. Simple Electrical stimulation tests 16.24.3. Lumbar puncture 16.24.4. others 16.25. Rest of South America Multiple Sclerosis Treatment Market Forecast, By Distribution Channel 16.25.1. Hospital Pharmacy 16.25.2. Retail Pharmacy 16.25.3. Online Stores 16.26. South America Multiple Sclerosis Treatment Market Attractiveness Analysis 16.26.1. By Drug Type 16.26.2. By Route of Administration 16.26.3. By Diagnosis 16.26.4. By Distribution Channel 16.27. PEST Analysis 16.28. Key Trends 16.29. Key Developments 17. Company Profiles 17.1. Market Share Analysis, by Company 17.2. Competition Matrix 17.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 17.2.2. New Product Launches and Product Enhancements 17.2.3. Market Consolidation 17.2.3.1. M&A by Regions, Investment and Applications 17.2.3.2. M&A Key Players, Forward Integration and Backward Integration 17.3. Company Profiles: Key Players 17.3.1. Bayer 17.3.1.1. Company Overview 17.3.1.2. Financial Overview 17.3.1.3. Product Portfolio 17.3.1.4. Business Strategy 17.3.1.5. Recent Developments 17.3.1.6. Development Footprint 17.3.2. Biogen 17.3.3. Merck KGaA 17.3.4. Teva 17.3.5. Sanofi 17.3.6. Novartis 17.3.7. Roche 17.3.8. Acorda Therapeutics, Inc. 17.3.9. EMD Serono (Merck KGaA) 17.3.10. AbbVie, Inc 17.3.11. Actelion 17.3.12. Celgene 17.3.13. AbbVie 17.3.14. Alkermes 17.3.15. TG Therapeutics 17.3.16. GeNeuro 17.3.17. Antisense Therapeutics 17.3.18. AB Science 17.3.19. MedDay 17.3.20. Coherus Bioscience 17.3.21. InnoBioscience 17.3.22. MediciNova 17.3.23. Santhera Pharmaceuticals 17.3.24. GSK 17.3.25. Ionis Pharmaceutical 18. Primary Key Insights

About This Report

Report ID 54201
Category Healthcare
Published Date March 2020
Updated Date
Contact Us